PURPOSE: Insulin-like growth factor-I (IGF-I) stimulates proliferation and inhibits apoptosis in prostate cancer cells, and IGF-I has been associated with increased prostate cancer risk in some, but not all, epidemiologic studies. SUBJECTS AND METHODS: We extended our previous case-control study nested in the Northern Sweden Health and Disease Cohort, a population-based cohort from a region where little prostate specific antigen (PSA) screening is done. Levels of IGF-I and IGF binding protein-3 (IGFBP-3) were measured in prediagnostic blood samples from a total of 281 men who were subsequently diagnosed with prostate cancer after recruitment (median, 5 years after blood collection) and from 560 matched controls. RESULTS: Logistic regression analyses showed increases in prostate cancer risk with increasing plasma peptide levels, up to an odds ratio (OR) for top versus bottom quartile of IGF-I of 1.67 (95% CI, 1.02 to 2.71; Ptrend = .05), which was attenuated after adjustment for IGFBP-3 to an OR of 1.47 (95% CI, 0.81 to 2.64; P (trend) =.32). For men younger than 59 years at recruitment, OR for top versus bottom quartile of IGF-I was 4.12 (95% CI, 1.01 to 16.70; Ptrend = .002), which was significantly stronger than for men older than 59 years (P (interaction) = .006). For men with advanced cancer, OR for top versus bottom quartile of IGF-I was 2.87 (95% CI, 1.01 to 8.12; Ptrend = .10). CONCLUSION: Our data add further support for IGF-I as an etiologic factor in prostate cancer and indicate that circulating IGF-I levels measured at a comparatively young age may be most strongly associated with prostate cancer risk. Copyright 2004 American Society of Clinical Onocology
PURPOSE:Insulin-like growth factor-I (IGF-I) stimulates proliferation and inhibits apoptosis in prostate cancer cells, and IGF-I has been associated with increased prostate cancer risk in some, but not all, epidemiologic studies. SUBJECTS AND METHODS: We extended our previous case-control study nested in the Northern Sweden Health and Disease Cohort, a population-based cohort from a region where little prostate specific antigen (PSA) screening is done. Levels of IGF-I and IGF binding protein-3 (IGFBP-3) were measured in prediagnostic blood samples from a total of 281 men who were subsequently diagnosed with prostate cancer after recruitment (median, 5 years after blood collection) and from 560 matched controls. RESULTS: Logistic regression analyses showed increases in prostate cancer risk with increasing plasma peptide levels, up to an odds ratio (OR) for top versus bottom quartile of IGF-I of 1.67 (95% CI, 1.02 to 2.71; Ptrend = .05), which was attenuated after adjustment for IGFBP-3 to an OR of 1.47 (95% CI, 0.81 to 2.64; P (trend) =.32). For men younger than 59 years at recruitment, OR for top versus bottom quartile of IGF-I was 4.12 (95% CI, 1.01 to 16.70; Ptrend = .002), which was significantly stronger than for men older than 59 years (P (interaction) = .006). For men with advanced cancer, OR for top versus bottom quartile of IGF-I was 2.87 (95% CI, 1.01 to 8.12; Ptrend = .10). CONCLUSION: Our data add further support for IGF-I as an etiologic factor in prostate cancer and indicate that circulating IGF-I levels measured at a comparatively young age may be most strongly associated with prostate cancer risk. Copyright 2004 American Society of Clinical Onocology
Authors: Katharina Nimptsch; Elizabeth A Platz; Michael N Pollak; Stacey A Kenfield; Meir J Stampfer; Walter C Willett; Edward Giovannucci Journal: Int J Cancer Date: 2011-02-01 Impact factor: 7.396
Authors: Fredrick R Schumacher; Iona Cheng; Matthew L Freedman; Lorelei Mucci; Naomi E Allen; Michael N Pollak; Richard B Hayes; Daniel O Stram; Federico Canzian; Brian E Henderson; David J Hunter; Jarmo Virtamo; Jonas Manjer; J Michael Gaziano; Laurence N Kolonel; Anne Tjønneland; Demetrius Albanes; Eugenia E Calle; Edward Giovannucci; E David Crawford; Christopher A Haiman; Peter Kraft; Walter C Willett; Michael J Thun; Loïc Le Marchand; Rudolf Kaaks; Heather Spencer Feigelson; H Bas Bueno-de-Mesquita; Domenico Palli; Elio Riboli; Eiliv Lund; Pilar Amiano; Gerald Andriole; Alison M Dunning; Dimitrios Trichopoulos; Meir J Stampfer; Timothy J Key; Jing Ma Journal: Hum Mol Genet Date: 2010-05-19 Impact factor: 6.150
Authors: Daniel Santa Mina; Michael K Connor; Shabbir M H Alibhai; Paul Toren; Crissa Guglietti; Andrew G Matthew; John Trachtenberg; Paul Ritvo Journal: Can Urol Assoc J Date: 2013 Nov-Dec Impact factor: 1.862
Authors: Makoto Anzo; Laura J Cobb; David L Hwang; Hemal Mehta; Jonathan W Said; Shoshana Yakar; Derek LeRoith; Pinchas Cohen Journal: Cancer Res Date: 2008-05-01 Impact factor: 12.701
Authors: Mari-Anne Rowlands; David Gunnell; Ross Harris; Lars J Vatten; Jeff M P Holly; Richard M Martin Journal: Int J Cancer Date: 2009-05-15 Impact factor: 7.396